Company profile
| Medical Strategy was founded in 1992 and is among the leading independent Healthcare Investment consultants in Europe. The funds advised by Medical Strategy were able to achieve top positions in a comparison of the performance and were distinguished several times among others by STANDARD & POORS; Lipper, EURO/FINANZEN, Feri Fund Research and Sauren Fonds-Research. Medical Strategy has in particular set itself the target to identify new trends in growth in the field of health at an early stage and through investments in young growth companies to achieve more than average results in the long-term. The team of Medical Strategy continuously analyzes and observes private (Pre-IPO) and listed companies in all relevant investment segments of the Healthcare sector (among others Pharma, Emerging Pharma, Biotech, Healthcare-Services, Medtech, Drug Delivery, E-Health). |
 Special focus is placed on the Small and Mid Cap area. More than 800 companies are systematically documented in a database. This information basis is constantly extended through In-House-Research and external special research. Medical Strategy has further the permission to operate the financial portfolio management by the German Federal Financial Supervisory Authority (BaFin). We are a member of the Association of Independent Asset Management Companies.  |
